Neonc Technologies (NASDAQ:NTHI) stockholders approved all voting matters presented at the company’s 2026 Annual Meeting of Stockholders, including the election of two Class 1 directors, an expansion of the company’s equity incentive plan, and the ratification of its independent accounting firm.
The virtual meeting was led by Amir Heshmatpour, the company’s chief executive officer, executive chairman and president. Heshmatpour said the meeting marked the company’s first annual meeting of shareholders.
Board Directors Elected
Stockholders elected Victoria Medvec, PhD, and Steven L. Giannotta, MD, as Class 1 directors. Each will serve a three-year term expiring at the company’s annual meeting in 2029, and until a successor is elected and qualified.
The company’s nominating and governance committee had recommended both candidates, and the board recommended that stockholders vote in favor of their election. Garnett said preliminary results showed both nominees had been duly elected.
Equity Plan Amendment Approved
Stockholders also approved an amendment to NeOnc’s 2023 equity incentive plan. The amendment increases the number of shares available for awards by an additional 1 million shares.
It also provides for annual increases in the plan’s share reserve beginning Jan. 1, 2027, and ending Jan. 1, 2033. Each annual increase would equal 20% of the company’s total common shares outstanding on the final day of the preceding calendar year.
The amendment required approval from a majority of shares present or represented by proxy and entitled to vote at the meeting. Garnett said the proposal was approved.
Auditor Appointment Ratified
Stockholders ratified the appointment of CBIZ CPAs, P.C. as NeOnc’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
The appointment also received the required majority approval from shares present in person or represented by proxy and entitled to vote, according to the preliminary voting results.
A fourth proposal would have authorized adjournment of the meeting if needed to secure sufficient votes or establish a quorum. Although the company did not present that proposal during the meeting because it had a quorum and sufficient votes for the other matters, Garnett said the proposal was approved for completeness of the record.
Heshmatpour said the company plans to file a Form 8-K with the Securities and Exchange Commission reporting the final voting results. No stockholder questions were submitted during the meeting.
About Neonc Technologies (NASDAQ:NTHI)
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
